Agreement provides option for
NEW BRUNSWICK, N.J.,
“The COVID-19 pandemic continues to threaten communities worldwide and we have a responsibility to ensure access to our COVID-19 vaccine as soon as we can. We appreciate the Commission’s and the Member States’ support for our COVID-19 vaccine candidate and development efforts,” said
This contract follows the conclusion of exploratory talks with the EC. The Company is in ongoing discussions with other stakeholders, including national governments and global organizations, as part of its efforts to meet its commitment to make its vaccine candidate accessible globally, provided the vaccine has a good safety profile, is efficacious and receives approval or authorization from regulators.
Separate to the agreement with the EC, as part of the Company’s larger commitment to respond to the COVID-19 pandemic,
Janssen’s investigational COVID-19 vaccine leverages Janssen’s AdVac® technology. The same technology was used to develop Janssen’s EC-approved Ebola vaccine regimen and is the basis for its HIV, RSV and Zika vaccine candidates. To date, more than 100,000 individuals have been vaccinated with a Janssen AdVac®-based vaccine. Based on our understanding of the stability of our vaccines, we anticipate our COVID-19 vaccine candidate to be compatible with standard distribution channels without the need for new distribution infrastructure.
For more information on
About the Janssen Pharmaceutical Companies
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of
Notice to Investors Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson–johnson-announces-european-commission-approval-of-agreement-to-supply-200-million-doses-of-janssens-covid-19-vaccine-candidate-301148577.html
Jake Sargent, +1 202-569-5086, JSargen3@its.jnj.com; Seema Kumar, +1 908-405-1144, SKumar10@its.jnj.com; Katie Buckley, +44 7900-655-261, KBuckle8@its.jnj.com; Investor Relations: Chris DelOrefice, +1 732-524-2955, Jennifer McIntyre, +1 732-524-3922